Foghorn Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Form 8-K dated July 8, 2021, reporting results of its 2021 Annual Meeting of Stockholders held on that date. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol FHTX.
Financial and Operating Metrics
This filing does not report revenue, earnings, cash flow, margins, debt, liquidity, or other operating or financial performance metrics. It states that 36,846,084 shares were entitled to vote and 28,665,401.97 shares were present or represented by valid proxy.
Material Changes Versus Prior Period
No comparative-period financial information or material operating changes are disclosed.
Meeting Results, Outlook, and Risks
- Scott Biller, Ph.D., Cigall Kadoch, Ph.D., and Michael Mendelsohn, M.D. were elected as Class I directors for three-year terms.
- Votes for the director nominees were 25,605,357.97, 25,474,272.98, and 25,531,488.99, respectively. Broker non-votes totaled 1,970,949 for the director elections.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- The auditor ratification received 28,654,447.97 votes for, 1,677 against, and 9,277 abstentions; there were no broker non-votes.
- The filing provides no financial guidance, clinical or commercial outlook, new risk disclosures, contingencies, or unusual accounting items.
Key Facts for Investor Verification
- Verify the elected directors’ terms and continuing board composition.
- Verify Deloitte & Touche LLP’s appointment for fiscal 2021.
- Review the June 1, 2021 proxy statement for detailed proposal descriptions and additional governance information.
- Use subsequent periodic filings to assess financial performance, liquidity, clinical progress, and updated risk factors, as these matters are not addressed in this 8-K.